![]() |
|
|
Forward to a colleague |
||
Access Full Stories Boehringer Ingelheim has witnessed Vitae Pharmaceuticals attack the same diabetes and obesity target as itself, only faster, and has decided to splash out for a piece of the action... Read Wyeth ups the ante with new proteomics method Researchers from Wyeth Research's Biological Technologies division have described how the use of a titania-affinity enrichment step can aid in the discovery of post-translational protein modifications... Read Orexo buys Biolipox for pain pipeline Drug formulation and delivery specialist Orexo has decided it has had enough of improving established drugs and wants to develop its own, so has bought speciality pharma firm Biolipox... Read Roche results up on oncology portfolio Roche announced its third quarter financials today, with its portfolio of oncology products such as Herceptin (trastuzumab) and Avastin (bevacizumab) performing strongly, and helping off-set the massive 60 per... Read Galapagos gains grants of €5.2m Galapagos and its services division BioFocus DPI have gained three new research grants totalling €5.2m... Read |
||||||||||||||||||
All News Headlines for: October | September | August |
||||||||||||||||||
Manufacturing Variations in Polysorbate Batches Lot to lot variances in a series of Polysorbate preparations was easily and clearly differentiated and identified by utilizing charged aerosol detection (CAD), a new universal detectorfor HPLC... Click Here | ||||||||||||||||||
|
Related Industry News Pfizer gets chatty with docs online Pfizer has gone where no pharmaceutical company has gone before - a social networking website... Read Results: 2007 European outsourcing awards The ten winners of the European outsourcing awards for 2007 were finally unveiled at the recently-held CPhI trade show in Milan... Read US dragging its heels on biosimilars, says report The US is woefully lagging behind the EU when it comes to approving biosimilars, a new report says... Read Paving the way to next generation biologics As biologic drugs become ever more prominent, Avecia Biologics is winning plaudits for its advanced protein expression system pAVEway, gaining recognition from international industry experts and investing to meet... Read
|
||||||||||||||||||
|
|||||
Forward to a colleague |
|||||
To continue to receive this newsletter in your inbox, please add newsletter@DrugResearcher.com to your address book |
||
Update preferences | Change your email address | Unsubscribe |
||
Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback |
||
| © 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com |
||